Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study
Universitat Autònoma de Barcelona · National Cancer Centre Japan · +19 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
953
total citations
- FWCI
- 45.45
- Percentile
- 100%
- References
- 26
Citations per year
Authors
19Topics & keywords
Topics
Keywords
- Bevacizumab
- FOLFIRI
- Ramucirumab
- Medicine
- Oxaliplatin
- Oncology
- Internal medicine
- Colorectal cancer
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.